Profile data is unavailable for this security.
About the company
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
- Revenue in USD (TTM)166.80m
- Net income in USD-29.73m
- Incorporated2019
- Employees180.00
- LocationArcturus Therapeutics Holdings Inc10628 Science Center Dr Ste 250SAN DIEGO 92121-1132United StatesUSA
- Phone+1 (858) 900-2660
- Fax+1 (302) 636-5454
- Websitehttps://arcturusrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics Inc | 2.83m | -43.56m | 685.00m | 53.00 | -- | 2.05 | -- | 242.39 | -10.77 | -10.77 | 0.4429 | 11.40 | 0.0173 | -- | -- | 53,320.75 | -26.72 | -41.40 | -28.86 | -44.70 | -- | -- | -1,541.22 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Savara Inc | 0.00 | -54.70m | 685.21m | 37.00 | -- | 4.88 | -- | -- | -0.3424 | -0.3424 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -34.47 | -36.86 | -36.36 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.158 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| enGene Holdings Inc | 0.00 | -106.80m | 685.97m | 33.00 | -- | 5.85 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
| Aurinia Pharmaceuticals Inc | 175.51m | -78.02m | 710.07m | 300.00 | -- | 1.87 | -- | 4.05 | -0.5454 | -0.5454 | 1.23 | 2.63 | 0.3445 | 0.439 | 9.34 | 585,043.30 | -15.31 | -25.97 | -17.42 | -28.24 | 91.94 | -- | -44.45 | -137.64 | 4.99 | -- | 0.1925 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Evolus Inc | 202.09m | -61.69m | 714.40m | 273.00 | -- | -- | -- | 3.54 | -1.08 | -1.08 | 3.55 | -0.3578 | 1.10 | 4.12 | 7.63 | 740,238.10 | -33.62 | -40.92 | -45.33 | -59.74 | 69.54 | 65.43 | -30.52 | -80.46 | 2.10 | -3.47 | 1.21 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Cabaletta Bio Inc | 0.00 | -67.68m | 730.86m | 101.00 | -- | 3.07 | -- | -- | -1.65 | -1.65 | 0.00 | 4.94 | 0.00 | -- | -- | 0.00 | -36.52 | -33.76 | -39.22 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 166.80m | -29.73m | 743.94m | 180.00 | -- | 2.66 | -- | 4.46 | -1.16 | -1.16 | 6.23 | 10.38 | 0.3792 | -- | 9.58 | 926,661.10 | -6.76 | -19.66 | -8.86 | -24.90 | -- | -- | -17.82 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Disc Medicine Inc | 0.00 | -76.43m | 747.34m | 74.00 | -- | 2.14 | -- | -- | -3.49 | -3.49 | 0.00 | 14.17 | 0.00 | -- | -- | 0.00 | -26.90 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| SAGE Therapeutics Inc | 86.46m | -541.49m | 755.54m | 487.00 | -- | 0.944 | -- | 8.74 | -9.05 | -9.05 | 1.44 | 13.32 | 0.0772 | -- | 1.79 | 177,527.70 | -48.37 | -21.88 | -52.66 | -23.30 | 97.50 | 99.63 | -626.32 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Tyra Biosciences Inc | 0.00 | -69.13m | 758.93m | 49.00 | -- | 3.04 | -- | -- | -1.62 | -1.62 | 0.00 | 4.75 | 0.00 | -- | -- | 0.00 | -28.10 | -- | -29.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -98.15m | 767.58m | 116.00 | -- | 1.98 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -153.16m | 770.01m | 85.00 | -- | 1.69 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Pliant Therapeutics Inc | 1.58m | -161.34m | 774.68m | 158.00 | -- | 1.63 | -- | 490.30 | -2.75 | -2.75 | 0.0269 | 7.90 | 0.0037 | -- | 1.59 | 10,000.00 | -37.40 | -33.24 | -39.82 | -35.39 | -- | -- | -10,211.14 | -360.29 | -- | -- | 0.0208 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| National Research Corporation | 148.58m | 30.96m | 795.40m | 435.00 | 26.53 | 16.48 | 21.57 | 5.35 | 1.26 | 1.26 | 6.02 | 2.02 | 1.18 | -- | 11.00 | 341,563.20 | 24.49 | 26.25 | 33.80 | 36.77 | 62.30 | 63.20 | 20.84 | 23.95 | -- | 1,929.64 | 0.4286 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| Tango Therapeutics Inc | 36.53m | -101.74m | 796.12m | 140.00 | -- | 3.01 | -- | 21.80 | -1.08 | -1.08 | 0.3865 | 2.48 | 0.0871 | -- | 36.53 | 260,907.10 | -24.25 | -- | -27.59 | -- | -- | -- | -278.54 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
Data as of Apr 18 2024. Currency figures normalised to Arcturus Therapeutics Holdings Inc's reporting currency: US Dollar USD
61.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 31 Dec 2023 | 4.71m | 17.51% |
| ARK Investment Management LLCas of 31 Dec 2023 | 2.05m | 7.61% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.93m | 7.17% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.63m | 6.06% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.42m | 5.27% |
| Nikko Asset Management Americas, Inc.as of 31 Dec 2023 | 1.32m | 4.91% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 1.09m | 4.05% |
| Woodline Partners LPas of 31 Dec 2023 | 1.07m | 3.98% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 864.36k | 3.21% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 554.20k | 2.06% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
